Zacks Investment ResearchT3·20d ago
SDGR Schrodinger, Inc. Common Stock
XNAS
24.50
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SDGR
$24.50
—
Key stats
$24.50
Pre-market
$24.80
+1.22%
- 52-Week Range
- $10.95 – $33.78
- YTD
- +36.26%
- IV Rank (30D)
- 83.23
- Straddle Price
- $5.03
- P/C Vol Ratio
- 0.31
- Market Cap
- $1.8B
- Open
- $23.89
- Day Range
- $23.26 – $24.89
- Volume
- 1,264,305
- Prev Close
- $23.80
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.57 |
| Cost of Equity (CAPM) | 13.58% (VRP-adj) |
| WACC | 13.73% |
| Volatility Risk Premium | +51.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +8.4% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.08 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -16.5% |
| Book / Price | 18.1% |
| Gross Margin (TTM) | 56.9% |
| FCF Margin (TTM) | -50.3% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $24.15 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $26.54 |
| Bollinger Width / SMA20 | 171.8% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $2B |
Peers used for multiples: CDNA, CRSP, GH, GPCR, LLY, NTRA, TWST, VCYT
60-Day Conviction
99%
20-Day Fair Value
≈ by Nov 25, 2026
$24.75
α +1.0%
rank 88%
conviction
60%
40-Day Fair Value
≈ by Dec 24, 2026
$25.37
α +3.6%
rank 87%
conviction
93%
60-Day Fair Value
≈ by Jan 22, 2027
$26.25
α +7.1%
rank 83%
conviction
99%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.7× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 28.3× · 3 peers |
| Peer P/B | $37.28 | 13% | median 8.4× · 7 peers |
| Peer P/S | $72.58 | 13% | median 19.2× · 7 peers |
| Market Anchor (SMA50) | $24.15 | 47% | stability 68% (BB-width) |
| Options Expected (B-L 30d) | $23.64 | 26% | 15 strikes · skew +0.26 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.8B
- Employees
- 850
- List Date
- 2020-02-06
- CIK
- 0001490978
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($0.65) (2 est.)
- Headquarters
- New York, NY
- Homepage
- https://www.schrodinger.com
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have vari…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 13.65% | -20.07% | 32.06% | -24.71% | 22.92% | -22.30% | 0.26% |
| Feb | 11.11% | 17.55% | -13.56% | -4.39% | -9.75% | -14.41% | -2.24% |
| Mar | -32.54% | -5.54% | 7.03% | 0.71% | -7.06% | -6.50% | -7.32% |
| Apr | -2.92% | -30.54% | 11.78% | -7.41% | 36.04% | 3.55% | 1.75% |
| May | -5.39% | -1.64% | 8.32% | -14.81% | -13.10% | 22.68% | -0.66% |
| Jun | 5.72% | 3.49% | 42.26% | -10.30% | -7.24% | 2.85% | 6.13% |
| Jul | -11.60% | 12.83% | 7.52% | 18.76% | -1.36% | -7.00% | 3.19% |
| Aug | -12.17% | -11.11% | -29.51% | -6.95% | -0.10% | 27.62% | -5.37% |
| Sep | -12.83% | -9.43% | -22.99% | -9.69% | 4.97% | 48.99% | -0.16% |
| Oct | 1.09% | -4.81% | -21.15% | -1.15% | -0.80% | -19.57%* | -7.73% |
| Nov | -31.66% | -27.10% | 42.52% | 25.46% | -14.55% | -- | -1.07% |
| Dec | -6.24% | 6.01% | 10.19% | -14.19% | 4.93% | -- | 0.14% |
| Total | -63.74% | -58.07% | 52.10% | -45.52% | 4.02% | 15.55% | -15.94% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $26.54
SMA 50: $24.15
SMA 200: $16.55
Current: $24.50
EMA 12: $24.64
EMA 26: $25.18
MACD: -0.5414 | Signal: -0.5497
BULLISH
ADX (14): 26.61
TREND
+DI: 19.58
−DI: 23.99
Momentum Oscillators
RSI (14): 47.53
NEUTRAL
Stoch %K: 21.91
Stoch %D: 16.36
Williams %R: -58.66
Volume & Volatility
BB Upper: $32.59
BB Lower: $20.49
NEUTRAL
OBV: 16,362,836
Vol SMA 20: 2,565,622
Vol ROC: -41.28%
ATR: $1.89
True Range: $1.63
HV 20: 82.6%
HV 30: 105.4%
HV 60: 87.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall Assessment: NEUTRAL (6/10) Key Drivers:
- Positive news sentiment from recent headlines
- Bullish momentum signals from MACD and Bollinger Bands Primary Risks:
- High volatility - stock moves more than market
- Uncertainty around earnings release
Investment Thesis: SDGR is a high-volatility stock with a strong technical setup, driven by positive news sentiment. While the stock may be overbought in the short term, its recent price action suggests a potential uptrend.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, highlighting the company's advancements in generative AI and biosimulation. This has contributed to the stock's upward momentum.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - UPTREND, Medium-term (1-3 months) - NEUTRAL, Long-term (3-12 months) - DOWNTREND
Support/Resistance Levels:
- Lower Bollinger Band: $17.40
- Middle Bollinger Band: $19.44
- Upper Bollinger Band: $21.48
- SMA 20: $19.44
- EMA 12: $19.83
Momentum Signals:
- MACD signal line crossover above zero (bullish)
- RSI interpretation: Neutral (54.37)
Volume Analysis:
- Volume SMA 20: 985698.00
- OBV: 9780568.03
- Volume Rate of Change: -72.71%
News & Sentiment Analysis
Recent Headlines Summary: The company's recent announcements have focused on its advancements in generative AI and biosimulation, highlighting the potential for positive future developments.
Sentiment Assessment: POSITIVE
Catalyst Identification: Earnings release (date TBA)
Market Narrative: The news sentiment has been largely positive, aligning with the stock's upward momentum. The company's recent announcements have contributed to this positivity.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock relative to market (beta 1.59 vs SPY)
Volatility Regime: Current volatility is higher than historical levels
Options Market Signals:
- IV Rank: 13.6% (Low)
- Put/Call Volume Ratio: 0.26 (Bullish sentiment)
Downside Protection: Support levels are at $17.40 and $19.44, with the lower Bollinger Band providing additional protection.
Market Context & Positioning
Sector Performance: SDGR is outperforming its sector peers
Institutional Activity: Volume patterns suggest institutional interest
Correlation Analysis: The stock has a moderate correlation with the market (R-squared 0.37)
Relative Valuation: The stock is relatively undervalued compared to its historical levels.
Key Levels & Action Items
Critical Price Levels: Support at $17.40 and $19.44, resistance at $21.48
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band could trigger further upward momentum, while a breakdown below the lower Bollinger Band would indicate a reversal.
Time-Sensitive Catalysts: Earnings release (date TBA)
Risk Management: Stop-loss levels should be set at $17.40 and $19.44, with position sizing considerations taking into account the stock's high volatility.
Generated
News
All SDGR news →
GlobeNewswire Inc.T3·22d ago
GlobeNewswire Inc.T3·1mo ago
GlobeNewswire Inc.T3·3mo ago
BenzingaT3·4mo ago
The Motley FoolT3·4mo ago
The Motley FoolT3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·9mo ago
The Motley FoolT3·10mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
19 of 23 under expected move
Avg Expected Move
15.63%
Avg Actual Move
8.42%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-04 | After-Close | 14.74% | 4.20% | 0.28x | Within |
| 2021-05-11 | After-Close | 9.56% | 3.34% | 0.35x | Within |
| 2021-08-12 | After-Close | 5.73% | 0.49% | 0.09x | Within |
| 2021-11-10 | After-Close | 12.80% | 11.73% | 0.92x | Within |
| 2022-02-24 | After-Close | 26.39% | 19.12% | 0.72x | Within |
| 2022-05-04 | After-Close | 17.86% | 8.22% | 0.46x | Within |
| 2022-08-04 | After-Close | 14.41% | 3.26% | 0.23x | Within |
| 2022-11-03 | After-Close | 14.23% | 15.17% | 1.07x | Exceeded |
| 2023-02-28 | After-Close | 9.20% | 13.21% | 1.44x | Exceeded |
| 2023-05-04 | After-Close | 13.65% | 8.13% | 0.60x | Within |
| 2023-08-02 | After-Close | 17.02% | 23.91% | 1.40x | Exceeded |
| 2023-11-01 | After-Close | 18.34% | 14.69% | 0.80x | Within |
| 2024-02-28 | After-Close | 16.61% | 18.84% | 1.13x | Exceeded |
| 2024-05-01 | After-Close | 15.84% | 8.19% | 0.52x | Within |
| 2024-07-31 | After-Close | 18.74% | 1.44% | 0.08x | Within |
| 2024-11-12 | Pre-Market | 15.86% | 13.87% | 0.87x | Within |
| 2025-02-26 | After-Close | 18.32% | 2.53% | 0.14x | Within |
| 2025-05-07 | After-Close | 15.91% | 0.67% | 0.04x | Within |
| 2025-08-06 | After-Close | 12.54% | 0.10% | 0.01x | Within |
| 2025-11-05 | After-Close | 21.50% | 5.67% | 0.26x | Within |
| 2026-02-25 | After-Close | 20.34% | 8.14% | 0.40x | Within |
| 2026-05-05 | Pre-Market | 15.50% | 0.23% | 0.01x | Within |
| 2026-08-05 | After-Close | 14.48% | 8.60% | 0.59x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SDGR Options Activity & IV Rank
SDGR IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 93.8%
7-DTE IV: —
Expected Move: $5.03
7-DTE Move: $5.03
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 331
Put Volume: 103
P/C Volume: 0.311
BULLISH
Call OI: 20,585
Put OI: 5,412
P/C OI: 0.263
Total OI: 25,997
ATM Options Pricing
ATM Call: $2.35
ATM Put: $2.67
Call %: 9.6%
Put %: 10.9%
Chain Summary
Chain Volume: 3,892
Chain OI: 44,938
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 64th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
64%
vs own history
GEX tilt
+0.53
OI-weighted, today
Vanna tilt
+0.51
δ-sensitivity to IV
Charm tilt
-0.51
δ-decay vs time
Vanna tilt +0.51: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.51: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 12 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
94%
+16.2
pts
EXTREME
as of Oct 26 · ATM 96.6% / Wing 112.8%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)83.2HighOct 26
Straddle Price (30 DTE)$5.03Oct 26
Beta Analysis
Risk Metrics
Beta: 1.5925
Alpha: 6.73%
Correlation: 0.3234
R-Squared: 10.5%
Stock Volatility: 62.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SDGR
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Gates Foundation Trust Foundation Bill Gates | $113.5M | #18 of 24 | 0.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $14.6M | #1339 of 6285 | +354.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $64K | #3232 of 4729 | +130.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SDGR Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 74,203,721 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
9 filers$11.83M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $4.89M | 41.33% | 2026-06-30 |
| 2 | PEAK6 LLC | $2.19M | 18.54% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $1.17M | 9.89% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $1.15M | 9.73% | 2025-09-30 |
| 5 | Citadel Advisors LLC Custodian | $778.38K | 6.58% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $586.62K | 4.96% | 2026-06-30 |
| 7 | Walleye Capital LLC | $505.38K | 4.27% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $388.38K | 3.28% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $167.38K | 1.42% | 2026-06-30 |
9 filers$8.83M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | PEAK6 LLC | $3.77M | 42.76% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $2.22M | 25.16% | 2026-06-30 |
| 3 | D. E. Shaw & Co., Inc. Custodian | $862.88K | 9.77% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $820.62K | 9.29% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $667.88K | 7.56% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $224.45K | 2.54% | 2025-09-30 |
| 7 | Walleye Capital LLC | $118.62K | 1.34% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $94.25K | 1.07% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $43.88K | 0.50% | 2026-06-30 |
SDGR Insider Trading (Form 4)
Latest: 2026-09-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Karen Akinsanya | See Remarks | Mixed | — | $16.85 | -$790.8K | EDGAR |
| 2026-07-17 | Rachit Jain | EVP & CFO | Sell (S) | −875 | $15.60 | -$13.6K | EDGAR |
| 2026-06-29 | Richard Friesner | Director | Gift (G) | — | — | EDGAR | |
| 2026-06-23 | Arun Oberoi | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Jeffrey Chodakewitz | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Gary L Ginsberg | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Nancy Thornberry | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Gary Sender | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Bridget A van Kralingen | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Richard Friesner | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Rosana Kapeller-Libermann | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-06-23 | Michael Lynton | Director | Award (A) | +8,141 | — | EDGAR | |
| 2026-04-17 | Rachit Jain | EVP & CFO | Sell (S) | −844 | $12.75 | -$10.8K | EDGAR |
| 2026-04-17 | Ramy Farid | President & CEO | Mixed | +74,527 | $6.28 | -$562.4K | EDGAR |
| 2026-03-06 | Rachit Jain | EVP & CFO | Sell (S) | −1,631 | $12.90 | -$21.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SDGR Insider Holdings
19 insiders · @ $24.50
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Richard Friesner | Director | 705,917 | $17.29M | -$37.96M | 12 | 2026-06-29 |
| 2 | Ramy Farid | President & CEO | 330,824 | $8.11M | -$12.37M | 12 | 2026-04-17 |
| 3 | Kenneth Patrick Lorton | EVP, CTO & COO, Software | 89,241 | $2.19M | -$3.49M | 22 | 2026-03-06 |
| 4 | Karen Akinsanya | See Remarks | 69,956 | $1.71M | -$7.64M | 17 | 2026-09-21 |
| 5 | Robert Lorne Abel | See Remarks | 55,897 | $1.37M | -$10.67M | 19 | 2026-03-06 |
| 6 | Yvonne Tran | EVP, CLO & CPO | 52,683 | $1.29M | -$6.88M | 19 | 2026-03-06 |
| 7 | Rachit Jain | EVP & CFO | 50,877 | $1.25M | -$45.4K | 5 | 2026-07-17 |
| 8 | Jenny Herman | CAO | 34,804 | $852.7K | -$463.3K | 18 | 2026-03-06 |
| 9 | Mannix Vartan Aklian | See Remarks | 31,193 | $764.2K | $0 | 2 | 2026-03-03 |
| 10 | Gary Sender | Director | 25,388 | $622.0K | -$1.91M | 8 | 2026-06-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SDGR Board & Officers
As of SEC filings through Sep 21, 2026Directors 10
- Gary Sender · since Feb 5, 2020
- Michael Lynton · since Feb 5, 2020
- Nancy Thornberry · since Feb 5, 2020
- Ramy Farid · since Feb 5, 2020
- Richard Friesner · since Feb 5, 2020
- Rosana Kapeller-Libermann · since Feb 5, 2020
- Gary L Ginsberg · since Apr 30, 2020
- Jeffrey Chodakewitz · since Apr 30, 2020
- Arun Oberoi · since May 17, 2022
- Bridget A van Kralingen · since Mar 7, 2025
Officers 8
- Ramy Farid · President & CEO · since Feb 5, 2020
- Karen Akinsanya · President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships · listed since Mar 2026
- Rachit Jain · EVP & CFO · since May 16, 2025
- Kenneth Patrick Lorton · EVP, CTO & COO, Software · listed since Feb 2024
- Margaret Dugan · Chief Medical Officer · since Jul 31, 2023
- Robert Lorne Abel · EVP, Chief Scientific Officer, Platform · listed since Mar 2024
- Yvonne Tran · EVP, CLO & Cpo · listed since May 2023
- Therese Marie Abrams · VP, Corporate Controller · since Mar 8, 2026
Changes in the last 10 years (53)
| May 18, 2026 | The company announced the departure of Mannix Vartan Aklian as EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing in an SEC filing |
| Mar 8, 2026 | Therese Marie Abrams became VP, Corporate Controller |
| Mar 6, 2026 | The company announced the departure of Jenny Herman as CAO in an SEC filing |
| Mar 3, 2026 | Karen Akinsanya listed as President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships (previously President of R&D, Therapeutics) in SEC filings |
| Feb 12, 2026 | Jenny Herman listed as CAO (previously SVP & Controller) in SEC filings |
| May 28, 2025 | Mannix Vartan Aklian became EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing |
| May 16, 2025 | The company announced the departure of Geoffrey Craig Porges as EVP & CFO in an SEC filing |
| May 16, 2025 | Rachit Jain became EVP & CFO |
| Mar 7, 2025 | Bridget A van Kralingen became a director |
| Mar 5, 2024 | Robert Lorne Abel listed as EVP, Chief Scientific Officer, Platform (previously EVP, Chief Computational Scientist, Head of Modeling R&D) in SEC filings |
| Feb 13, 2024 | Kenneth Patrick Lorton listed as EVP, CTO & COO, Software (previously EVP & Chief Technology Officer) in SEC filings |
| Jul 31, 2023 | Margaret Dugan became Chief Medical Officer |
| May 24, 2023 | Yvonne Tran listed as EVP, CLO & Cpo (previously EVP & Chief Legal Officer) in SEC filings |
| Feb 10, 2023 | Karen Akinsanya listed as President of R&D, Therapeutics (previously EVP, Chief Biomedical Scientist, Head of Discovery R&D) in SEC filings |
| Aug 18, 2022 | Geoffrey Craig Porges became EVP & CFO |
| May 17, 2022 | Arun Oberoi became a director |
| Dec 16, 2021 | The company announced the departure of Joel Lebowitz as EVP & CFO in an SEC filing |
| Jul 19, 2021 | Schrodinger Equity Holdings, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 19, 2021 | David E Shaw reported in an SEC filing no longer being a 10% owner |
| Mar 2, 2021 | Robert Lorne Abel listed as EVP, Chief Computational Scientist, Head of Modeling R&D (previously EVP, Science) in SEC filings |
| Mar 2, 2021 | Kenneth Patrick Lorton listed as EVP & Chief Technology Officer (previously Senior Vice President and Chief Technology Officer) in SEC filings |
| Mar 2, 2021 | Jenny Herman listed as SVP & Controller (previously Vice President, Controller) in SEC filings |
| Mar 2, 2021 | Jennifer Daniel listed as EVP & Chief HR Officer (previously SVP & Chief HR Officer) in SEC filings |
| Feb 2, 2021 | Jennifer Daniel listed as SVP & Chief HR Officer (previously Senior Vice President and Chief Human Resources Officer) in SEC filings |
| Apr 30, 2020 | Jeffrey Chodakewitz became a director |
| Apr 30, 2020 | Gary L Ginsberg became a director |
| Feb 10, 2020 | Richard Friesner no longer listed as a 10% owner in SEC filings |
| Feb 10, 2020 | Ramy Farid no longer listed as a 10% owner in SEC filings |
| Feb 5, 2020 | Yvonne Tran became EVP & Chief Legal Officer |
| Feb 5, 2020 | Timothy Michael Wright became a director |
| Feb 5, 2020 | Shane Brauner became Senior Vice President and Chief Information Officer |
| Feb 5, 2020 | Schrodinger Equity Holdings, LLC became a 10% owner |
| Feb 5, 2020 | Rosana Kapeller-Libermann became a director |
| Feb 5, 2020 | Robert Lorne Abel became EVP, Science |
| Feb 5, 2020 | Richard Friesner became a director |
| Feb 5, 2020 | Richard Friesner became a 10% owner |
| Feb 5, 2020 | Ramy Farid became a director |
| Feb 5, 2020 | Ramy Farid became a 10% owner |
| Feb 5, 2020 | Ramy Farid became President & CEO |
| Feb 5, 2020 | Nancy Thornberry became a director |
| Feb 5, 2020 | Michael Lynton became a director |
| Feb 5, 2020 | Kenneth Patrick Lorton became Senior Vice President and Chief Technology Officer |
| Feb 5, 2020 | Karen Akinsanya became EVP, Chief Biomedical Scientist, Head of Discovery R&D |
| Feb 5, 2020 | Jorg Weiser became EVP & Managing Director |
| Feb 5, 2020 | Joel Lebowitz became EVP & CFO |
| Feb 5, 2020 | Jenny Herman became Vice President, Controller |
| Feb 5, 2020 | Jennifer Daniel became Senior Vice President and Chief Human Resources Officer |
| Feb 5, 2020 | Gary Sender became a director |
| Feb 5, 2020 | David E Shaw became a 10% owner |
| Feb 5, 2020 | Cony D'Cruz became Executive Vice President and Chief Business Officer |
| Feb 5, 2020 | Charles Ardai became a 10% owner |
| Feb 5, 2020 | Bill & Melinda Gates Foundation Trust became a 10% owner |
| Feb 5, 2020 | 2018 Grat Rf became a 10% owner |
Not reported recently (8)
- Charles Ardai · Last reported as a 10% owner in an SEC filing dated Apr 26, 2021
- Jorg Weiser · Last reported as EVP & Managing Director in an SEC filing dated Apr 2, 2021
- Jennifer Daniel · Last reported as EVP & Chief HR Officer in an SEC filing dated Apr 2, 2021
- Cony D'Cruz · Last reported as Executive Vice President and Chief Business Officer in an SEC filing dated Mar 24, 2021
- Shane Brauner · Last reported as Senior Vice President and Chief Information Officer in an SEC filing dated Mar 2, 2021
- Bill & Melinda Gates Foundation Trust · Last reported as a 10% owner in an SEC filing dated Nov 27, 2020
- Timothy Michael Wright · Last reported as a director in an SEC filing dated Feb 10, 2020
- 2018 Grat Rf · Last reported as a 10% owner in an SEC filing dated Feb 5, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SDGR Proposed Insider Sales (Form 144)
Latest: 2026-09-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $756K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
KAREN OLUFUNMILYO AKINSANYA-AKIWUMI (1, $756K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-17 | KAREN OLUFUNMILYO AKINSANYA-AKIWUMI | Officer | 31,599 | $756.2K | 2026-09-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-16 | Jain Rachit | Officer | 875 | $13.6K | 2026-07-16 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-07-01 | Aklian Mannix Vartan | Officer | 1,136 | $18.9K | 2026-07-01 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-01 | Herman Jenny | Officer | 1,957 | $24.0K | 2026-05-01 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-04-16 | Jain Rachit | Officer | 844 | $10.8K | 2026-04-16 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-04-16 | RAMY SAMIR FARID | Director, Officer | 86,000 | $1.07M | 2026-04-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-06 | Herman Jenny | Officer | 608 | $7.8K | 2026-03-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-05 | Lorton Kenneth Patrick | Officer | 1,222 | $15.8K | 2026-03-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-05 | Tran Yvonne | Officer | 1,094 | $14.1K | 2026-03-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-03-05 | Herman Jenny | Officer | 775 | $10.0K | 2026-03-05 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
75 ETFs hold SDGR
25 shown · $376.19M total exposure · 0.06% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.08% | $80.9M | $104.0B | 2026-10-23 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $61.0M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.02% | $43.6M | — | 2026-09-30 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.05% | $34.8M | $74.6B | 2026-10-23 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.06% | $24.3M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $20.1M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.09% | $12.9M | $13.7B | 2026-10-23 |
| 8 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.17% | $12.6M | $7.6B | 2026-10-23 |
| 9 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.08% | $12.4M | $15.8B | 2026-10-23 |
| 10 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.06% | $10.4M | — | 2026-09-30 |
| 11 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.17% | $7.7M | $4.6B | 2026-10-23 |
| 12 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.50% | $6.6M | $1.3B | 2026-10-23 |
| 13 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.10% | $6.3M | — | 2026-09-30 |
| 14 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.1M | — | 2026-09-30 |
| 15 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.02% | $5.5M | — | 2026-10-23 |
| 16 | JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF | JPMorgan | 0.18% | $5.3M | $2.9B | 2026-10-26 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.05% | $4.1M | — | 2026-10-23 |
| 18 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $4.1M | — | 2026-05-31 |
| 19 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.06% | $3.7M | $6.6B | 2026-10-23 |
| 20 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.10% | $2.6M | $2.7B | 2026-10-23 |
| 21 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.19% | $2.6M | $1.4B | 2026-10-23 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.5M | — | 2026-10-23 |
| 23 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 0.17% | $2.3M | $1.4B | 2026-10-23 |
| 24 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $2.0M | $96.5B | 2026-10-23 |
| 25 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.12% | $2.0M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.74
TTM Revenue
$259.04M
TTM Net Income
$-54.34M
TTM Op. Cash Flow
$-126.87M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $58.89M | $5.97M | $0.08 | $-34.07M |
| Q1 '26 | 2026-03-31 | $58.59M | $-60.03M | $-0.81 | $-14.83M |
| Q4 '25 | 2025-12-31 | $87.23M | $32.51M | $0.44 | $-16.09M |
| Q3 '25 | 2025-09-30 | $54.32M | $-32.80M | $-0.45 | $-61.87M |
| Q2 '25 | 2025-06-30 | $54.76M | $-43.17M | $-0.59 | $-52.20M |
| Q1 '25 | 2025-03-31 | $59.55M | $-59.81M | $-0.82 | $144.06M |
| Q4 '24 | 2024-12-31 | $88.32M | $-40.22M | $-0.55 | $-31.11M |
| Q3 '24 | 2024-09-30 | $35.29M | $-38.14M | $-0.52 | $-33.26M |
| Q2 '24 | 2024-06-30 | $47.33M | $-54.05M | $-0.74 | $-53.72M |
| Q1 '24 | 2024-03-31 | $36.60M | $-54.72M | $-0.76 | $-39.28M |
| Q4 '23 | 2023-12-31 | $74.13M | $-30.67M | $-0.41 | $-37.26M |
| Q3 '23 | 2023-09-30 | $42.57M | $-62.02M | $-0.86 | $-49.94M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
5.53
P/S
7.02
EV/EBITDA
—
EV/Sales
5.91
ROE
-16.5%
ROA
-8.5%
Div Yield
0.00%
FCF Yield
-6.98%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$1.82B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
10.13M
SI % of Float
19.33%
Days to Cover
3.07
Short Vol Ratio
50.3%
Free Float
52.41M
Float %
80.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-05-15